HomeFinTechRecce Pharmaceuticals: Expands and accelerates clinical programs

Recce Pharmaceuticals: Expands and accelerates clinical programs

Date:

SMBC and Fujitsu Join Forces for AI-Powered Data Analytics Solutions

Exploring the Impact of Innovative Partnerships in the Financial...

Global Spending on Financial Market Data Reaches $44.3 Billion

Exploring the Factors Driving the Surge in Financial Data...

Visa Unveils Innovative AI Fraud-Fighting Tool

Revolutionizing Payment Security with Advanced Technology Highlights: Visa introduces a...

Recce Pharmaceuticals Expands and accelerates clinical programs

  • Recce Pharmaceuticals (RCE) updates its clinical timeline, with several data read-outs expected over this year and next year
  • The company expects to dose its first subject under a phase 1b/2a multi-dose and early-stage sepsis study later this year
  • Meanwhile, new data from antoher phase one clinical trial of R327 supports findings from pre-clinical in-vivo kidney and UTI bacterial infection studies
  • Furthermore, Recce has designed a new phase two study for R327 for treating diabetic foot ulcer infections, with the first patient to be dosed before the end of the year
  • Shares in ReccePharmaceuticals are trading 6.15 per cent higher at 69 cents each at 2:59 pm AEST
Exit mobile version